Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person1
Merck & Co., Inc.
Company
Primary record20
Teads Holding Co. filed 8-K
Item 2.02. Results of Operations and Financial Condition. On November 5, 2026, Teads Holding Co. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2026. Informati
Merck & Co., Inc. filed 4
SEC form 4 filed by Merck & Co., Inc. (CIK 310158) on 2026-11-03.
Merck & Co., Inc. filed 8-K
Item 2.02. Results of Operations and Financial Condition . The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02. Incorporated by reference is a press release issued by M
Entera Bio Ltd. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of Dr. Juan Camilo Arjona Ferreira as Director On Oc
Silence Therapeutics plc filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. Transaction Agreement On October 18, 2026, Silence Therapeutics plc, a public limited company incorporated in England and Wales (the “ Company ”), entered into a tran
Merck & Co., Inc. filed 25-NSE
0000876661-26-000834.txt : 20261015 25-NSE 1 primary_doc.xml X0203 0000876661 NEW YORK STOCK EXCHANGE LLC 0000310158 Merck & Co., Inc. 001-06571 126 EAST LINCOLN AVE Rahway NJ NEW JERSEY 07065 (908) 740-4000 1.875% Notes
Merck & Co., Inc. filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Incorporated by reference is a press release issued by Mer
Entera Bio Ltd. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of Laura Hamill as Director On October 6, 2026, the
Merck & Co., Inc. filed 4
SEC form 4 filed by Merck & Co., Inc. (CIK 310158) on 2026-10-01.
BIO-TECHNE Corp filed 8-K
Item 5.07 Submission of Matters to a Vote of Security Holders. On September 23, 2026, Bio-Techne Corporation, a Minnesota corporation ( Bio-Techne ), held a special meeting of shareholders (the Special Meeting ) to consi
Avalyn Pharma Inc. filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Director On September 15, 2026 (the Effective Da
Perspective Therapeutics, Inc. filed 8-K
Item 8.01 Other Events. On September 14, 2026, Perspective Therapeutics, Inc. issued a press release announcing a clinical collaboration and supply agreement with Merck. A copy of the press release is filed as Exhibit 99
BIO-TECHNE Corp filed 8-K
Item 8.01. Other Events. As previously disclosed, on June 25, 2026, Bio-Techne Corporation, a Minnesota corporation ( Bio-Techne ), entered into an Agreement and Plan of Merger (the Merger Agreement ) with Merck KGaA, Da
Pyxis Oncology, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 9, 2026, Pyxis Oncology, Inc. (the “Company”) provided a corporate update and issued a press release announcing updated data from its ongoing global Phase 1 monotherapy st
Stablecoin Development Corp filed 8-K
Item 3.03. Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information set forth in Item 5.03 of this Current Report is incorporated by reference herein. Item 5.0
Azenta, Inc. filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of President and Chief Executive Officer On August
Venu Holding Corp filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. On August 16, 2026 (the “ Effective Date ”), Venu Holding Corporation (the “ Company ”) entered into a Binding Term Sheet (the “ Term Sheet ”) with Hipgnosis Artist H
Edible Garden AG Inc filed 8-K
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 11, 2026, Kostas Dafoulas resigned as Interim Chief F
Merck & Co., Inc. filed 4
SEC form 4 filed by Merck & Co., Inc. (CIK 310158) on 2026-08-13.
Merck & Co., Inc. filed 4
SEC form 4 filed by Merck & Co., Inc. (CIK 310158) on 2026-08-13.